Trial Profile
Immunogenicity, Reactogenicity and Safety Study of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) When Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal meningitis
- Focus Pharmacodynamics
- Acronyms MENACWY CONJ-069; MENACWY CONJ-069 (V59_78)
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
- 11 Nov 2022 Results (n=2669) of a pooled post analysis from two clinical studies (NCT03652610 and NCT03433482) using safety data from participants aged 10-40 years who received one dose of either liquid MenACWY-CRM or licensed MenACWY-CRM published in the Drug Safety
- 16 Jan 2020 Status changed from active, no longer recruiting to completed.
- 05 Dec 2019 This trial has been completed in Spain, according to European Clinical Trials Database record.